

## Sacral neuromodulation therapy with the Medtronic InterStim™ systems

### For faecal incontinence



#### Faecal Incontinence (FI)

FI is characterised by recurring, uncontrollable episodes of **involuntary loss of solid or liquid faecal material**.<sup>1,2</sup>

FI is **highly prevalent** (5-11%<sup>3-8</sup> of adults and up to 17%<sup>9</sup> in those aged  $\geq 75$  years) and it **negatively impacts patients health-related quality of life**.<sup>10</sup>

The **social stigma and embarrassment** experienced by patients makes FI a **hidden condition**, with only a small proportion of patients (15-49%) seeking treatment.<sup>3,11</sup>



#### Current treatment management

The goal of FI management is to restore continence and improve health-related quality of life.<sup>12</sup>

FI is **initially managed conservatively** (e.g. supportive care, education, medications).<sup>2,13</sup> If these measures are unsuccessful, patients move to more specialised measures (e.g. biofeedback, pelvic floor muscle training) and in some cases to surgical options, including Sacral Neuromodulation (SNM).

Although SNM requires surgery, it is considerably **less invasive** than the other surgical management options.<sup>14</sup>

### Benefits of Sacral Neuromodulation (SNM)

- Helps to **restore normal bowel function**<sup>15-17</sup>
- Offers **short term evaluation** for a possible **stable long term solution**<sup>18</sup>
- Effects are **reversible**<sup>19</sup>
- Improves patients **quality of life**<sup>28</sup>



SNM with InterStim™ systems is **internationally endorsed**<sup>2,13,20-24</sup>

### Medtronic InterStim™ systems



Supported by over **1,000 clinical articles** and over **90 clinical studies**



**400,000\*** patients treated with Medtronic InterStim™ systems



**Almost 30 years experience** managing FI patients with incremental innovation

- InterStim™ Micro is rechargeable with up to 15 years battery life
- InterStim X™ recharge-free neurostimulator with >10 years of battery life<sup>9</sup> and up to 15 years under low energy settings<sup>5</sup>



InterStim™ Micro and InterStim X™ systems

# SNM with the Medtronic InterStim™ systems



**3 RCT<sup>†,25-27</sup> and 50 observational studies<sup>‡</sup>**



**Long-term effectiveness**  
over 10 years<sup>18,28,30-32</sup>



Usually **≥80%** of patients have **≥50% improvement**<sup>28,29</sup>



Established **safety** profile<sup>18,25,26,28,29,33-38</sup>



Up to **47%** of patients are **completely continent** after 12 months<sup>25</sup>



According to **cost-effectiveness evidence**, SNM may provide **value for money** when added to the treatment algorithm of FI<sup>39-43</sup>

## References

1. Deutekom, M et al. Am. J. Gastroenterol. 102, 351-361 (2007)
2. Cardozo, L al. Incontinence 7th Edition. (ICI-ICS. International Continence Society, 2023)
3. Damon, H et al. Gastroenterol. Clin. Biol. 30, 37-43 (2006)
4. Whitehead, WE et al. Gastroenterology 137, 512-517.e2 (2009)
5. Nygaard, I et al. JAMA 300, 1311-1316 (2008)
6. Buckley, BS & Lapitan, MC. Int. J. Clin. Pract. 63, 568-573 (2009)
7. Walter, S et al. Scand. J. Gastroenterol. 37, 911-6 (2002)
8. Sharma, A et al. Br J Surg, 103:1589-1597 (2016).
9. Stenzelius, K et al. NeuroUrol. Urodyn. 23, 211-22 (2004)
10. Mundet, L et al. J. Neurogastroenterol. Motil. 22, 94-101 (2016)
11. Horng, SS et al. NeuroUrol. Urodyn. 33, 1153-1158 (2014)
12. Rao, SS et al. Am. J. Gastroenterol. 99, 1585-1604 (2004)
13. NICE. Faecal incontinence in adults: management. (2007)
14. Hetzer, FH. Color. Dis. 13, 1-4 (2011)
15. Gourcerol G. et al. Colorectal Dis. 13(8): e203-11 (2011)
16. Sheldon, R et al. Br. J. Surg. 92, 1423-1431 (2005)
17. Carrington EV & Knowles CH. Colorectal Dis. 2011 Mar;13 Suppl 2:5-9
18. Janssen, PT et al. Surgery 161, 1040-1048 (2017)
19. NHS England. Clinical Commissioning Policy: Sacral Nerve Stimulation for Overactive Bladder. (2015)
20. Bordeianou, LG, IM et al. Dis. Colon Rectum 66(5):647-661 (2023)
21. Matzel KE (2017) in: Herold A et al. Coloproctology. European Manual of Medicine. DOI 10.1007/978-3-662-53210-2
22. Wald, A et al. Am J Gastroenterol, 116, 1987-2008 (2021)
23. Vitton, V et al. Color Dis, 16, 159-166 (2014).
24. Assmann, SL et al. United Eur Gastroenterol J, 10, 251-286 (2022)
25. Tjandra, JJ et al. Dis. Colon Rectum 51, 494-502 (2008)
26. Thin, NN et al. Br. J. Surg. 102, 349-358 (2015)
27. Rydningen, M et al. Color Dis, 19, O134-O144 (2017).
28. Hull, T. et al. Dis. Colon Rectum 56, 234-245 (2013).
29. Matzel, KE et al. Lancet 363, 1270-1276 (2004)
30. Widmann, B et al. J Neurogastroenterol Motil, 25, 159-170 (2019).
31. De Meyere, C et al. Tech Coloproctol, 24, 947-958 (2020).
32. Desprez, C et al. Color Dis, 24, 754-763 (2022).
33. Feretis, M. J. Interv. Gastroenterol. 3, 82 (2013)
34. Jarrett, ME et al. Br. J. Surg. 91, 755-761 (2004)
35. Mellgren, A. et al. Dis. Colon Rectum 54, 1065-1075 (2011)
36. Duelund-Jakobsen, J. et al. Int. J. Colorectal Dis. 31, 421-428 (2016)
37. Michelsen, HB et al. Dis. Colon Rectum 53, 414-421 (2010)
38. Ismail, MB et al. Medico-Legal Update 21(1), 575-579 (2021)
39. Dudding, T C et al. Br. J. Surg. 95, 1155-1163 (2008)
40. Brosa, M. et al. Curr. Med. Res. Opin. 24, 907-18 (2008)
41. Indinnimeo, M. et al. Dis. Colon Rectum 53, 1661-1669 (2010)
42. van Wunnik, BPet al. Color. Dis. 14, e807-e814 (2012)
43. de Miguel Valencia, MJ, Cirugia Espanola (English Ed, 100, 422-430) (2022)

\*As of InterStim™ Implant Numbers, version 2.0, July-2023

† RCT: Randomised Controlled Trial. 1 comparing SNM to conservative management,<sup>25</sup> 1 comparing SNM to Percutaneous Tibial Nerve Stimulation<sup>26</sup> and 1 comparing SNM to injection of bulking agents<sup>27</sup>

‡ For the full list of the available literature on InterStim™ therapy for FI and additional information please consult the following Medtronic brochure: "Sacral Neuromodulation therapy with the InterStim™ System for Faecal Incontinence - Value Summary" (UC202403021EE). Please contact your Medtronic Representative to get the document.

Ω Under expected therapy settings and telemetry use

§ Please see System Eligibility, Battery Longevity, Specifications manual for battery longevity estimates.

See the device manual for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. If using an MRI SureScan® device, see the MRI SureScan® technical manual before performing an MRI. For further information, contact your local Medtronic representative and/or consult the Medtronic website at [www.medtronic.com](http://www.medtronic.com).



[www.medtronic.com/manuals](http://www.medtronic.com/manuals)

Consult instructions for use at this website. Manuals can be viewed using a current version of any major Internet browser. For best results, use Adobe Acrobat Reader® with the browser.

## Medtronic

**Europe**  
Medtronic International Trading Sàrl.  
Route du Molliau 31  
Case postale  
CH-1131 Tolochenaz  
Tel: +41 (0)21 802 70 00  
Fax: +41 (0)21 802 79 00

**United Kingdom/Ireland**  
Medtronic Limited  
Building 9  
Croxley Park  
Hatters Lane  
Watford  
Herts WD18 8WW  
[www.medtronic.co.uk](http://www.medtronic.co.uk)  
Tel: +44 (0)1923 212213  
Fax: +44 (0)1923 241004

UC201904741aEE © Medtronic 2023.  
All rights reserved.